Excessive screen time is linked to heart health risks in kids, research shows
Published in the Journal of the American Heart Association Wednesday, the research found 10- and 18-year-olds who spent more time focused on devices, including phones, televisions, computers and gaming consoles, were at higher risk for cardiometabolic diseases, including high blood pressure, high cholesterol and insulin resistance.
The study used data from more than 1,000 participants in two Danish studies. Researchers gave a score to each participant representing their risk for the diseases compared to the average risk of the group, measured in standard deviations, with 0 meaning average risk and 1 meaning one standard deviation above average.
Each extra hour of screen time increased the patient's overall risk by about 0.08 standard deviations in 10-year-olds and by 0.13 standard deviations in 18-year-olds, the study's authors said.
"It's a small change per hour, but when screen time accumulates to three, five or even six hours a day, as we saw in many adolescents, that adds up," lead author David Horner, a researcher at the University of Copenhagen in Denmark, said in a news release.
Researchers found 18-year-olds were on devices about 6 hours a day, on average, while 10-year-olds averaged 3 hours a day.
They also found sleep impacted the results, with both less sleep and later bedtimes amplifying the relationship between screen time and heart health risks. That suggests screen time may harm health by "stealing" time from sleep, they said.
"Limiting discretionary screen time in childhood and adolescent may protect long-term heart and metabolic health," Horner said. "Our study provides evidence that this connection starts early and highlights the importance of having balanced daily routines."
The research was observational, meaning it found associations rather than proved cause and effect. It also had some limitations, including that participants self-reported screen time, which might not accurately reflect how much time they were actually on devices.
It adds to a growing body of research about the possible effects of screen time and digital devices on young people's health and well-being. In 2023, the U.S. surgeon general urged parents to create "tech-free zones" for kids.
More than half of states now have laws in place to restrict or ban cellphones in schools, and several more have proposed similar legislation.
Quadruple murder suspect captured in Tennessee, officials confirm
State Department puts out request for foreign nutrition aid
Breaking down the crime drop reported by FBI
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization
Sitryx regains rights to SYX-1042 itaconate mimetic for chronic autoimmune and inflammatory diseases from Lilly following portfolio reprioritization Novel, oral candidate with first-in-class potential progresses successfully through Lilly's Phase 1 clinical trial in healthy volunteers Sitryx reintegrates SYX-1042 into portfolio of novel small molecule candidates targeting major autoimmune indications with high unmet need Oxford, UK – 8 August 2025 – Sitryx Therapeutics ('the Company'), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces that the Company has regained the rights to its itaconate mimetic, SYX-1042, for the treatment of chronic autoimmune and inflammatory diseases, from Eli Lilly & Company (Lilly), due to strategic considerations and reprioritization of Lilly's pain and inflammation portfolio. In 2024 Lilly commenced a Phase 1 first-in-human study of SYX-1042, a post-translational modification modulator program for chronic autoimmune and inflammatory diseases, following a research collaboration between the two companies. That study has completed successfully. With the return to Sitryx of SYX-1042, its phase 2-ready data package and associated API, Sitryx is assessing how best to prioritize SYX-1042 for continued in-house development or potential further partnering. Iain Kilty, Chief Executive Officer of Sitryx, commented: 'Through our partner Lilly's investment in the clinical development of SYX-1042, this program has progressed significantly, delivering positive first-in-human data. We will be reviewing this clinical data alongside the robust preclinical data package to determine the optimal path forward. We thank Lilly for this collaboration and the advances we made together, progressing important research into a first-in-class candidate which we believe holds exciting potential in multiple chronic autoimmune and inflammatory diseases.' -Ends- For more information about Sitryx please contact: ICR HealthcareMary-Jane Elliott, David Daley +44 (0)20 3709 5700Sitryx@ About SitryxSitryx is a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease. The Company has a broad pipeline of novel small molecule candidates targeting major autoimmune indications with high unmet need. Its lead candidate, SYX-5219, is a potentially first-in-class PKM2 modulator in development for atopic dermatitis as a once-daily oral therapy with future development potential across multiple autoimmune diseases. Established in 2018 with seed funding from SV Health Investors, Sitryx has raised $85 million to date from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly and Company, and GSK. Sitryx is headquartered in Oxford, UK. For more information, please visit in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
43 minutes ago
- Bloomberg
Heat Waves Are a Growing Threat to Europe's Nuclear Power Supply
Heat waves across Europe are increasing the need for nuclear power plants to be taken offline, with the situation expected to worsen in the coming decades and few options for mitigation. Weather-related nuclear outages, mainly caused by elevated temperatures of cooling water, increased threefold in the period from 2010 to 2019, compared with 1990 to 2009, according to a study published in Energy Economics. Due to climate change, the intensity and length of these heat waves is expected to increase.
Medscape
an hour ago
- Medscape
Transplanted Islet Cells Survive Without Immune Suppression
For the first time, researchers have transplanted gene-edited donor islet cells that secrete insulin in a person with type 1 diabetes (T1D) without the use of immunosuppression. Twelve-week results from the phase 1, single-participant study were published online on August 4, 2025, as a Brief Report in The New England Journal of Medicine . Six-month data were presented on June 23, 2025, at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago and announced at the time in a press release from Sana Biotechnology. The study subject, a 42-year-old man with a 37-year history of T1D, has shown no immune response to the gene-edited cells and has maintained ongoing significant circulating C-peptide levels, a measure of insulin secretion, in contrast to zero at baseline. MRI at 12 weeks confirmed persistence of the grafted hypoimmune islets. At 6 months, increased C-peptide levels in response to a mixed-meal tolerance test were seen. He still requires insulin treatment, but that was expected because the protocol for this early safety study involved delivery of only 7% of the number of cells that would be curative, lead author Per-Ola Carlsson, MD, PhD, senior physician and professor at the Clinic for Endocrinology and Diabetology at Uppsala University Hospital, Uppsala, Sweden, told Medscape Medical News . 'Excited,' but 'Many Hurdles to Overcome' Currently, transplantation for treatment of T1D — whether of whole pancreas, cadaveric donor islets, or experimental stem cell-derived islets — is reserved for individuals with frequent severe hypoglycemia or those who are already undergoing another transplant, such as a kidney. In most people with managed T1D, the adverse health risks for immune suppression are viewed as outweighing the benefits of a transplant. In T1D, transplantation provokes two immune system attacks: one against any foreign body, which is common to all organ transplants (allogeneic), and a second to the beta cell-specific autoantibodies that caused the condition in the first place. Thus far, it appears that this novel gene-editing approach overcomes both allogeneic and autoimmune rejection. If upcoming trials using stem cell-derived islets that can be produced in unlimited quantities validate these results, this approach could essentially represent a cure for many people T1D, Carlsson said. 'I have never been so excited in my life. I've been working with the science since the 1990s, and this is the one project that has been so positive and so convincing. I'm really happy to work with it, and since I'm a clinician, it's magic to be able to do something that could turn into a reality for these patients,' he told Medscape Medical News . However, he cautioned, 'This is one subject…we believe it is applicable to all subjects with type 1 diabetes. But of course, there may be subgroups that it does not work for.' Moreover, he noted, 'It will take time before it reaches clinical reality.' Experts in the field contacted by Medscape Medical News expressed cautious optimism. Mark A. Atkinson, PhD, the ADA Eminent Scholar for Diabetes Research and professor in the Department of Pathology at the University of Florida, Gainesville, Florida, said, 'I am very enthusiastic about this study. I think this is a baby step, with the potential for moving forward a full leap. Time will tell. At a minimum, this shows that genetic modification of a stem cell source may prove valuable as a future therapeutic for type 1 diabetes.' However, Atkinson noted that because the treatment is likely to be expensive, 'the cost versus benefit ratio of using such a therapy across the spectrum of type 1 diabetes needs further exploration.' Islet cell transplantation pioneer A.M. James Shapiro, MD, Canada Research Chair in Transplantation Surgery and Regenerative Medicine at the University of Alberta, Edmonton, Alberta, told Medscape Medical News 'This is indeed an exciting development in that human insulin-producing islet cells continued to secrete, albeit small amounts of insulin in the absence of immune suppression. Ongoing research will determine whether this approach can be effectively scaled up and engraftment improved.' David M. Harlan, MD, director of the Breakthrough T1D Barbara D. Cammett Center of Excellence in New England and co-director of the University of Massachusetts (UMass) Diabetes Center of Excellence, Worcester, Massachusetts, said, 'I believe that the genetic modifications of stem cell-derived islets and/or a druggable target within a stem cell-derived islet is likely to represent a practical cure for type 1 diabetes in the next decade or so. I'm excited by this step, but I still see many hurdles to overcome.' Hypoimmune Islets: Breakthrough or Baby Step? Some of the 'hurdles' cited by Harlan, who is also the William and Doris Krupp Professor of Medicine at UMass, relate to the gene-editing procedure itself and to some of the study methodology. The islets, from a deceased donor with the same blood type as the recipient, were first dissociated into single cells, and the genes encoding human leukocyte antigen (HLA) class I and class II were inactivated using clustered regularly interspaced short palindromic repeat. The cells were reclustered, again dissociated, and transduced with a lentiviral vector containing CD47 complementary DNA. Knocking out HLA class I and II is necessary to protect against adaptive T-cell rejection, while overexpression of CD47 inhibits innate killing via macrophages and natural killer cells, Carlsson explained. According to Harlan, even without HLA class I and II, there would still be other cell surface molecules that would be expected to provoke an antibody response. 'I just don't understand why they don't see any donor-specific antibodies against the gene-modified islets. That doesn't make sense to me. Maybe such antibodies would be benign, but I would still expect them to be picked up.' Carlsson countered, 'Detection of foreign cells is through HLA. Other antigens…are, even if not encoded from the HLA class I or class II genes, presented to the immune system by the HLA molecules.' Atkinson noted that the autoimmune response could take much longer to occur than the allogeneic, and therefore longer follow-up is needed. Carlsson said that the planned follow-up is 15 years, but prior data suggest that the autoimmunity would occur within 1-2 months, and 'we didn't see any attack at all.' Harlan also noted that the patient's high baseline A1c, 10.9%, was unusual and might have adversely affected the findings. Carlsson said that this was per request of the regulatory bodies because such an individual would 'gain most from the development of a curing therapy considering their high risk of complications.' He added that this requirement 'complicated the study since high glucose stresses the beta cells…we were, however, able to improve his metabolic control post-transplantation.' The gene-edited cells were delivered with 17 separate injections — to allow for sufficient oxygen exposure — into the patient's forearm while he was under general anesthesia. Both Harlan and Atkinson questioned the feasibility of that approach going forward. Carlsson said that the forearm was chosen because it was simpler to monitor for safety, but that in future studies abdominal muscles might be used. Sana Biotechnology will not study this product, UP421, further. Instead, they are moving forward with SC451, a stem cell-derived pancreatic gene-edited islet cell product. The next study is still being planned but will involve multiple patients at more than one clinical site, Carlsson told Medscape Medical News . Atkinson commented, 'Over 50 years ago, individuals with type 1 diabetes were told that a cure was on the way, and it was going to occur through islet cell transplantation and understanding of the autoimmune nature of type 1 diabetes. There were animal models of the disease, and there were new classes of drugs that came out, namely cyclosporine. So, people had hopes that a cure for type 1 diabetes was 3-5 years away. Now, six decades later, we're still struggling with that, but there's promise on the horizon.' Carlsson and Shapiro reported having no disclosures. Atkinson is a consultant for Vertex, Sanofi, Diamyd, Novo Nordisk, and Sernova. Harlan is co-founder and chief scientific officer for Stability Health, LLC; a consultant for CG Scientific, Inc.; and chair of the scientific advisory board for TIXiMED.
